468 related articles for article (PubMed ID: 29389748)
21. Autism Spectrum Disorder: A Review.
Hirota T; King BH
JAMA; 2023 Jan; 329(2):157-168. PubMed ID: 36625807
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis.
Fung LK; Mahajan R; Nozzolillo A; Bernal P; Krasner A; Jo B; Coury D; Whitaker A; Veenstra-Vanderweele J; Hardan AY
Pediatrics; 2016 Feb; 137 Suppl 2():S124-35. PubMed ID: 26908468
[TBL] [Abstract][Full Text] [Related]
23. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
Bushe C; Day K; Reed V; Karlsdotter K; Berggren L; Pitcher A; Televantou F; Haynes V
J Psychopharmacol; 2016 May; 30(5):444-58. PubMed ID: 27005307
[TBL] [Abstract][Full Text] [Related]
24. Assessment and treatment of attention-deficit/hyperactivity disorder: part 2.
French WP
Pediatr Ann; 2015 Apr; 44(4):160-8. PubMed ID: 25875981
[TBL] [Abstract][Full Text] [Related]
25. Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders.
Rizzo R; Pavone P
Expert Rev Neurother; 2016 Aug; 16(8):867-74. PubMed ID: 27388494
[TBL] [Abstract][Full Text] [Related]
26. An update on medication management of behavioral disorders in autism.
Baribeau DA; Anagnostou E
Curr Psychiatry Rep; 2014 Mar; 16(3):437. PubMed ID: 24488702
[TBL] [Abstract][Full Text] [Related]
27. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
Pringsheim T; Hirsch L; Gardner D; Gorman DA
Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
[TBL] [Abstract][Full Text] [Related]
28. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.
Lamberti M; Siracusano R; Italiano D; Alosi N; Cucinotta F; Di Rosa G; Germanò E; Spina E; Gagliano A
Paediatr Drugs; 2016 Aug; 18(4):319-29. PubMed ID: 27278054
[TBL] [Abstract][Full Text] [Related]
29. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
30. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.
Hellings JA; Arnold LE; Han JC
Expert Opin Pharmacother; 2017 Apr; 18(6):581-588. PubMed ID: 28335658
[TBL] [Abstract][Full Text] [Related]
31. Aggressive behaviors and treatable risk factors of preschool children with autism spectrum disorder.
Chen C; Shen YD; Xun GL; Cai WX; Shi LJ; Xiao L; Wu RR; Zhao JP; Ou JJ
Autism Res; 2017 Jun; 10(6):1155-1162. PubMed ID: 28266803
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
Fredriksen M; Peleikis DE
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
[TBL] [Abstract][Full Text] [Related]
33. Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study.
Tjon Pian Gi CV; Broeren JPA; Starreveld JS; A Versteegh FG
Eur J Pediatr; 2003 Jul; 162(7-8):554-555. PubMed ID: 12783318
[No Abstract] [Full Text] [Related]
34. Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
Magalotti SR; Neudecker M; Zaraa SG; McVoy MK
Curr Psychiatry Rep; 2019 Nov; 21(12):123. PubMed ID: 31741142
[TBL] [Abstract][Full Text] [Related]
35. Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder?
Jerome L
J Child Adolesc Psychopharmacol; 2001; 11(1):109. PubMed ID: 11322740
[No Abstract] [Full Text] [Related]
36. Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents.
Stepanova E; Dowling S; Phelps M; Findling RL
Dialogues Clin Neurosci; 2017 Dec; 19(4):395-402. PubMed ID: 29398934
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Intermittent Explosive Disorder With Carbamazepine.
Coskun F; Akca OF
Clin Neuropharmacol; 2018; 41(2):82-83. PubMed ID: 29533363
[No Abstract] [Full Text] [Related]
38. Pharmacogenomics of autism spectrum disorder.
Brown JT; Eum S; Cook EH; Bishop JR
Pharmacogenomics; 2017 Mar; 18(4):403-414. PubMed ID: 28244813
[TBL] [Abstract][Full Text] [Related]
39. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
[TBL] [Abstract][Full Text] [Related]
40. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Chou TL; Chia S; Shang CY; Gau SS
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
